Evidence map›Paper›PMID 31053413›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2019

Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.

Victoria A Jennings, Gina B Scott, Ailsa M S Rose, Karen J Scott, Gemma Migneco, Brian Keller, Katrina Reilly, Oliver Donnelly, Howard Peach, Donald Dewar and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 57 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Tuning epigenetics to enhance cancer virotherapy.Acta pharmaceutica Sinica. B · 2026
    Review
  4. Review
  5. Review
  6. Oncolytic viruses: advanced strategies in cancer therapy.Signal transduction and targeted therapy · 2026
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Advances in NK cell therapy for brain tumors.NPJ precision oncology · 2023
    Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Victoria A JenningsThe Institute of Cancer Research, Division of Radiotherapy and Imaging, Chester Beatty Laboratories, London SW3 6JB, UK; Section of Infection and Immunity, Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK.
Gina B ScottSection of Infection and Immunity, Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK.
Ailsa M S RoseSection of Infection and Immunity, Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK.
Karen J ScottSection of Infection and Immunity, Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK.
Gemma MignecoSection of Infection and Immunity, Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK.
Brian KellerOttawa Hospital Research Institute, Ottawa, ON, Canada.
Katrina ReillySection of Infection and Immunity, Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK.
Oliver DonnellySection of Infection and Immunity, Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK.
Howard PeachSt James's University Hospital, Leeds LS9 7TF, UK.
Donald DewarSt James's University Hospital, Leeds LS9 7TF, UK.
Kevin J HarringtonThe Institute of Cancer Research, Division of Radiotherapy and Imaging, Chester Beatty Laboratories, London SW3 6JB, UK.
Hardev PandhaLeggett Building, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7WG, UK.
Adel SamsonSection of Infection and Immunity, Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK.
Richard G VileMayo Clinic, Rochester, MN 55905, USA.
Alan A MelcherThe Institute of Cancer Research, Division of Radiotherapy and Imaging, Chester Beatty Laboratories, London SW3 6JB, UK. Electronic address: alan.melcher@icr.ac.uk.
Fiona Errington-MaisSection of Infection and Immunity, Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK.
University of Leeds · GBInstitute of Cancer Research · GBSt James's University Hospital · GBMayo Clinic in Arizona · USOttawa Hospital · CAUniversity of Surrey · GB

Funding

Cancer Research UK 21855Cancer Research UK 29039Yorkshire Cancer Research L374RA
6 · The paper itself

Abstract

A clinical oncolytic herpes simplex virus (HSV) encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), talimogene laherparepvec, causes regression of injected and non-injected melanoma lesions in patients and is now licensed for clinical use in advanced melanoma. To date, limited data are available regarding the mechanisms of human anti-tumor immune priming, an improved understanding of which could inform the development of future combination strategies with improved efficacy. This study addressed direct oncolysis and innate and adaptive human immune-mediated effects of a closely related HSV encoding GM-CSF (HSV

Indexed as

Antigens, NeoplasmAntineoplastic Agents, ImmunologicalBiological ProductsCell SurvivalDendritic CellsDrug Therapy, CombinationGenetic VectorsGranulocyte-Macrophage Colony-Stimulating FactorHerpesvirus 1, HumanHistone Deacetylase InhibitorsHumansInterferon Type IKiller Cells, NaturalMCF-7 CellsMelanomaOncolytic VirotherapyAntigens, NeoplasmAntineoplastic Agents, ImmunologicalBiological ProductsCSF2 protein, humanGranulocyte-Macrophage Colony-Stimulating FactorHistone Deacetylase InhibitorsInterferon Type Italimogene laherparepvecValproic Acidherpes simplex virushistone deacetylase inhibitorHSV,cancer immunotherapyoncolytic virusvalproic acidVPA

Identifiers

PMID31053413
PMCPMC6554638
OpenAlexW2938047855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.